#We don't have to wait any more Closed-loop systems: transforming the landscape

Hybrid closed-loop systems are transforming the clinical management of T1DM. Large randomised controlled trials of hybrid closed-loop systems have demonstrated safety and efficacy, with significant improvements in glycaemic control compared to control therapy, and there are now several commercially approved hybrid closed-loop systems available in the UK. There is also a growing body of evidence demonstrating the quality of life benefits associated with hybrid closed-loop systems, both for users and also for parents/caregivers and other family members. We review the clinical evidence supporting currently available hybrid closed-loop systems in the UK and also new systems on the horizon. We discuss the emerging evidence for associated psychosocial benefits of hybrid closed-loop therapy. We also address future challenges around healthcare professional readiness to deliver closed-loop technology and ensuring equitable access across the UK.

[1]  C. Beaufort,et al.  Randomized trial of closed-loop control in very young children with type 1 diabetes , 2022, Yearbook of Paediatric Endocrinology.

[2]  R. Paul,et al.  Open-Source Automated Insulin Delivery in Type 1 Diabetes. , 2022, The New England journal of medicine.

[3]  E. Wilmot,et al.  Impact of glycaemic technologies on quality of life and related outcomes in adults with type 1 diabetes: A narrative review , 2022, Diabetic medicine : a journal of the British Diabetic Association.

[4]  Janet M. Allen,et al.  Lived experience of CamAPS FX closed loop system in youth with type 1 diabetes and their parents , 2022, Diabetes, obesity & metabolism.

[5]  Lauren M. Huyett,et al.  How Introduction of Automated Insulin Delivery Systems May Influence Psychosocial Outcomes in Adults with Type 1 Diabetes: Findings from the First Investigation with the Omnipod® 5 System. , 2022, Diabetes research and clinical practice.

[6]  R. Beck,et al.  Positive Impact of the Bionic Pancreas on Diabetes Control in Youth 6-17 Years Old with Type 1 Diabetes: A Multicenter Randomized Trial. , 2022, Diabetes technology & therapeutics.

[7]  B. Buckingham,et al.  Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial , 2022, Diabetes care.

[8]  Janet M. Allen,et al.  Parents' experiences of using a hybrid closed-loop system (CamAPS FX) to care for a very young child with type 1 diabetes: qualitative study. , 2022, Diabetes research and clinical practice.

[9]  R. Hovorka,et al.  Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. , 2022, The Lancet. Digital health.

[10]  R. Hovorka,et al.  Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study , 2022, The Lancet. Healthy longevity.

[11]  Grant J. Smith,et al.  Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. , 2021, JAMA pediatrics.

[12]  B. Buckingham,et al.  Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes , 2021, Diabetes Care.

[13]  Janet M. Allen,et al.  User Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics , 2021, Diabetes Care.

[14]  R. Hovorka,et al.  Adolescents’ and their parents’ experiences of using a closed-loop system to manage type 1 diabetes in everyday life: qualitative study , 2021, Chronic illness.

[15]  R. Beck,et al.  A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial , 2021, The Lancet.

[16]  L. Leelarathna,et al.  Hybrid closed‐loop therapy: Where are we in 2021? , 2020, Diabetes, obesity & metabolism.

[17]  Sybil A. McAuley,et al.  Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial , 2020, Diabetes Care.

[18]  R. Beck,et al.  A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. , 2020, The New England journal of medicine.

[19]  S. Zoungas,et al.  Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis , 2020, Diabetes Care.

[20]  R. Hovorka,et al.  Health professionals' views about who would benefit from using a closed‐loop system: a qualitative study , 2020, Diabetic medicine : a journal of the British Diabetic Association.

[21]  R. Hovorka,et al.  Who Should Access Closed-Loop Technology? A Qualitative Study of Clinician Attitudes in England , 2020, Diabetes technology & therapeutics.

[22]  Eyal Dassau,et al.  Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. , 2019, The New England journal of medicine.

[23]  Darrell M. Wilson,et al.  One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System , 2019, Diabetes Care.

[24]  F. Doyle,et al.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range , 2019, Diabetes Care.

[25]  Janet M. Allen,et al.  Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery , 2019, Diabetes Care.

[26]  Pierre Jallon,et al.  Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. , 2019, The Lancet. Digital health.

[27]  R. Hovorka,et al.  Women’s Experiences of Day-and-Night Closed-Loop Insulin Delivery During Type 1 Diabetes Pregnancy , 2018, Journal of diabetes science and technology.

[28]  R. Hovorka,et al.  Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis , 2018, British Medical Journal.